Groowe Groowe / Newsroom / BMY
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

BMY News

Bristol-Myers Squibb Co.

Ability Biotherapeutics nomme Angèle Maki, Ph. D., au poste de cheffe de la direction commerciale

businesswire.com
BMY GENK MRK LLY

Senior Pharma and Biotech Leaders to Convene for Industry Forum at San Francisco CEO Ahead of JP Morgan Healthcare Conference

accessnewswire.com
JPM JNJ AMGN MRK BMY REGN

BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer

globenewswire.com
BNTX BMY

Scancell updated Phase 2 data shows continued improvement in progression free survival with iSCIB1+ in patients with first line advanced melanoma

globenewswire.com
GILD BMY

Bristol Myers Squibb Advances Lymphoma Research with New Targeted Protein Degradation and Cell Therapy Data at ASH 2025

businesswire.com
BMY

Eczema Clinical Trial Pipeline Accelerates as 100+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

globenewswire.com
AMGN PFE LLY AZN BMY NVS SNY GSK UCB ARQT REGN INCY ABBV BIIB MRK JNJ VNDA RAPT CHAI ONON ION ASMB CRVS APG KSCP KYMR XBI IBB ADSK CDNS SNPS

Global Demand Spurs Competition in CAR T-Cell Therapy for Multiple Myeloma

globenewswire.com
BMY JNJ NVS GILD

John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO), to Deliver Keynote Address on the Future of Biotech and Rare Disease Innovation at the 2026 MDA Clinical & Scientific Conference

globenewswire.com
AMGN REGN GILD BMY AZN NVS ARGX BIIB BBIO SRRK

K36 Therapeutics announces presentation of First-in-Human Clinical Data for Gintemetostat (KTX-1001) Demonstrating Target Engagement and Clinical Activity in Multiple Myeloma at ASH 2025 and the Appointment of Dr. Shinta Cheng, M.D., Ph.D., as Chief

prnewswire.com
SWX JNJ BMY

Immunotherapy Drugs Research Report 2025: $526.5 Bn Market Opportunities, Growth Drivers, Industry Trend Analysis, and Forecast 2024-2034

globenewswire.com
AMGN PFE JNJ BMY GILD MRK MDT ADAP